Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
Allurion Technologies attracts buy ratings from financial analysts, with Roth MKM at $2.00 and Chardan Capital at $2.50.
Allurion Technologies (NYSE: ALUR), which focuses on obesity solutions, has attracted attention from financial analysts.
Roth MKM initiated coverage with a buy rating and a $2.00 price target, while Chardan Capital lowered its target from $5.00 to $2.50 but maintained a buy rating.
The company reported earnings of $0.01 per share and revenue of $11.77 million.
Institutional investors hold about 21.39% of its stock.
3 Articles
Allurion Technologies atrae las calificaciones de los analistas financieros, con Roth MKM a $2.00 y Chardan Capital a $2.50.